Beijing Beilu Pharmaceutical (300016) - Total Liabilities
Based on the latest financial reports, Beijing Beilu Pharmaceutical (300016) has total liabilities worth CN¥852.80 Million CNY (≈ $124.79 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Beijing Beilu Pharmaceutical cash conversion from operations to assess how effectively this company generates cash.
Beijing Beilu Pharmaceutical - Total Liabilities Trend (2005–2024)
This chart illustrates how Beijing Beilu Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. Check Beijing Beilu Pharmaceutical asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Beijing Beilu Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Beijing Beilu Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Luokai Mechanical & Electrical Co Ltd Class A
SHG:603829
|
China | CN¥1.88 Billion |
|
Apogee Enterprises Inc
NASDAQ:APOG
|
USA | $603.74 Million |
|
Gold Royalty Corp.
NYSE MKT:GROY
|
USA | $180.52 Million |
|
Shenzhen Kaizhong Precision Technology Co Ltd
SHE:002823
|
China | CN¥1.57 Billion |
|
Cantaloupe Inc
NASDAQ:CTLP
|
USA | $126.77 Million |
|
Jiangxi Salt Industry Group Co. Ltd. A
SHG:601065
|
China | CN¥1.18 Billion |
|
Aspen Group
AU:APZ
|
Australia | AU$187.81 Million |
|
Westlake Chemical Partners LP
NYSE:WLKP
|
USA | $454.18 Million |
Liability Composition Analysis (2005–2024)
This chart breaks down Beijing Beilu Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Beijing Beilu Pharmaceutical market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beijing Beilu Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beijing Beilu Pharmaceutical (2005–2024)
The table below shows the annual total liabilities of Beijing Beilu Pharmaceutical from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.15 Billion ≈ $167.99 Million |
+11.12% |
| 2023-12-31 | CN¥1.03 Billion ≈ $151.18 Million |
+15.78% |
| 2022-12-31 | CN¥892.27 Million ≈ $130.57 Million |
+9.05% |
| 2021-12-31 | CN¥818.22 Million ≈ $119.73 Million |
-14.37% |
| 2020-12-31 | CN¥955.50 Million ≈ $139.82 Million |
+451.32% |
| 2019-12-31 | CN¥173.31 Million ≈ $25.36 Million |
+108.99% |
| 2018-12-31 | CN¥82.93 Million ≈ $12.13 Million |
+15.74% |
| 2017-12-31 | CN¥71.65 Million ≈ $10.48 Million |
+31.71% |
| 2016-12-31 | CN¥54.40 Million ≈ $7.96 Million |
-53.66% |
| 2015-12-31 | CN¥117.39 Million ≈ $17.18 Million |
-51.22% |
| 2014-12-31 | CN¥240.67 Million ≈ $35.22 Million |
+293.50% |
| 2013-12-31 | CN¥61.16 Million ≈ $8.95 Million |
+2.56% |
| 2012-12-31 | CN¥59.64 Million ≈ $8.73 Million |
+79.71% |
| 2011-12-31 | CN¥33.19 Million ≈ $4.86 Million |
+343.20% |
| 2010-12-31 | CN¥7.49 Million ≈ $1.10 Million |
-57.46% |
| 2009-12-31 | CN¥17.60 Million ≈ $2.58 Million |
-33.62% |
| 2008-12-31 | CN¥26.52 Million ≈ $3.88 Million |
-48.36% |
| 2007-12-31 | CN¥51.36 Million ≈ $7.52 Million |
-5.07% |
| 2006-12-31 | CN¥54.10 Million ≈ $7.92 Million |
+26.55% |
| 2005-12-31 | CN¥42.75 Million ≈ $6.26 Million |
-- |
About Beijing Beilu Pharmaceutical
Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride … Read more